data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Cellectis
(NASDAQ:CLLS)
$2.75
At close: Jul 6
$2.70
-0.0500[-1.82%]
PreMarket: 7:09AM EDT
Day High/Low- - -
52 Week High/Low2.3 - 15.84
Open / Close- / -
Float / Outstanding- / 45.5M
Vol / Avg.0.3K / 140.4K
Mkt Cap125.1M
P/E-
50d Avg. Price3.22
Div / Yield-
Payout Ratio-
EPS-0.7
Total Float45M

Cellectis (NASDAQ:CLLS), Quotes and News Summary

Cellectis (NASDAQ: CLLS)

Day High/Low- - -
52 Week High/Low2.3 - 15.84
Open / Close- / -
Float / Outstanding- / 45.5M
Vol / Avg.0.3K / 140.4K
Mkt Cap125.1M
P/E-
50d Avg. Price3.22
Div / Yield-
Payout Ratio-
EPS-0.7
Total Float45M
Benzinga - May 24, 2022, 7:42AM
Benzinga - May 18, 2022, 6:08AM
Benzinga - May 13, 2022, 8:26AM
Benzinga - May 12, 2022, 5:13PM
Benzinga - Apr 27, 2022, 12:51PM
Benzinga - Apr 11, 2022, 12:15PM
Benzinga - Apr 8, 2022, 4:33PM
Benzinga - Mar 23, 2022, 10:06AM
Benzinga - Mar 18, 2022, 10:09AM
Benzinga - Mar 17, 2022, 10:46AM
Benzinga - Mar 16, 2022, 9:21AM
Benzinga - Mar 15, 2022, 4:03PM
Benzinga - Mar 11, 2022, 10:07AM
Benzinga - Mar 10, 2022, 10:48AM
Benzinga - Mar 3, 2022, 5:13PM
Benzinga - Mar 3, 2022, 4:47PM
Benzinga - Mar 3, 2022, 4:47PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.640
REV3.832M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Cellectis Questions & Answers

Q
How do I buy Cellectis (CLLS) stock?
A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Cellectis's (CLLS) competitors?
Q
What is the target price for Cellectis (CLLS) stock?
A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 2.00 expecting CLLS to fall to within 12 months (a possible -27.27% downside). 6 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Cellectis (CLLS)?
A

The stock price for Cellectis (NASDAQ: CLLS) is $2.75 last updated July 6, 2022, 8:00 PM UTC.

Q
Does Cellectis (CLLS) pay a dividend?
A

There are no upcoming dividends for Cellectis.

Q
When is Cellectis (NASDAQ:CLLS) reporting earnings?
A

Cellectis’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Cellectis (CLLS) going to split?
A

There is no upcoming split for Cellectis.

Q
What sector and industry does Cellectis (CLLS) operate in?
A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.